SEELQ.US Seelos Therapeutics, Inc.
- Market cap
- USD 5.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.
Is SEELQ.US undervalued?
Graham numberThe Graham number of Seelos Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Seelos Therapeutics, Inc. fundamental analysis
No fundamental analysis for Seelos Therapeutics, Inc. yet.
Seelos Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the trea…
Full company profileSeelos Therapeutics, Inc. financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Seelos Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -18.8M | -61.7M | -70.9M | -40.5M | -18.4M |
| EBITDA | - | -64.5M | -73.5M | -37.8M | - |
| Net Income | -19.1M | -66.0M | -73.5M | -37.9M | -1.91M |
| EPS | -1,345 | -2,404 | -2,635 | -31 | -9.19 |
| Balance Sheet | |||||
| Total Assets | 17.5M | 83.5M | 22.7M | 5.42M | 2.38M |
| Total Liabilities | 14.9M | 26.2M | 33.4M | 38.9M | 30.5M |
| Shareholders' Equity | 2.57M | 57.3M | -10.6M | -33.5M | -28.1M |
| Cash & Short-term Investments | 15.7M | 78.7M | 15.5M | 3.00M | 294K |
| Cash Flow | |||||
| Operating Cash Flow | -20.9M | -49.0M | -61.6M | -23.9M | -11.2M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -20.9M | -49.0M | -61.6M | -23.9M | -11.2M |
| Ratios | |||||
| ROE | -742.7% | -115.2% | - | - | - |
| ROA | -109.2% | -79.1% | -323.3% | -699.2% | -80.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Seelos Therapeutics, Inc. dividends
Seelos Therapeutics, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:16 on Sep 27, 2024.
Who owns Seelos Therapeutics, Inc.
Ownership data of Seelos Therapeutics, Inc. is not available yet.
Seelos Therapeutics, Inc. company profile
- Company name
- Seelos Therapeutics, Inc.
- Ticker
- SEELQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 300 Park Avenue, New York, NY, United States, 10022
- Phone
- 646 293 2100
- Website
- seelostherapeutics.com
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Seelos Therapeutics, Inc. management
5- Dr. Raj Mehra J.D., Ph.D.CEO, Founder, President & Chairman · born 1960
- Mr. Michael J. GolembiewskiChief Financial Officer · born 1971
- Mr. Anthony MarcianoChief Communications Officer
- Mr. Gopal Krishna Ph.D.Head of Manufacturing & Technical Operations
- Ms. Karen FusaroSenior VP & Head of Clinical Operations